Indivior Pharmaceuticals (INDV) EBT (2024 - 2026)

Indivior Pharmaceuticals' EBT history runs 3 years deep, the most recent figure standing at $115.0 million for Q1 2026.

• In Q1 2026, EBT rose 94.92% year-over-year to $115.0 million; the TTM figure through Mar 2026 stood at $295.0 million (up 4816.67% YoY), while the FY2025 annual figure was $239.0 million, up 1095.0% from the prior year.
• EBT was $115.0 million for Q1 2026 at Indivior Pharmaceuticals, up from $81.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $115.0 million in Q1 2026 to a low of -$121.0 million in Q2 2024.
• Historically, EBT has averaged $41.6 million across 3 years, with a median of $59.0 million in 2025.
• Biggest YoY gain for EBT was 151.24% in 2025; the steepest drop was 19.18% in 2025.
• A 3-year view of EBT shows it stood at $38.0 million in 2024, then soared by 113.16% to $81.0 million in 2025, then soared by 41.98% to $115.0 million in 2026.
• The last three EBT figures came in at $115.0 million (Q1 2026), $81.0 million (Q4 2025), and $37.0 million (Q3 2025), per Business Quant data.